The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.

The treatment the posts refer to, Gilead Sciences’ long-acting injectable drug lenacapavir, has been found in trials to be highly effective at preventing HIV infection when used as pre-exposure ...

Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

This agreement will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to ...

It is the first time that a PrEP trial has been shown to prevent any HIV infections from slipping through the net, according to Gilead, and showed a subcutaneous injection with lenacapavir every ...

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...